The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > ARCHIVE
ARCHIVE
- Prior Assessment Consultation System Started on Full Scale April 1
April 11, 2011
- DSP Licenses Anti-MRSA Drug from Takeda
April 11, 2011
- New Subsidiary in Slovenia to Manage Business in SE Europe: Astellas
April 11, 2011
- AZ Appeals to Tokyo High Court in Iressa Affair
April 11, 2011
- DSP Licenses INT-747 from Intercept
April 11, 2011
- Sandoz K.K. Begins Importing Substitute for Thyradin
April 11, 2011
- JPMA Revises Its Compliance Program GL to Ensure Good Compliance of Group Companies
April 11, 2011
- Eli Lilly Japan Confident about Becoming Top 10 Company by 2020
April 11, 2011
- Meiji, Fujirebio Terminate Joint Sales Agreement
April 11, 2011
- Korosho Calls For Restraint in Use of EN Products Due to Shortage of Ensure
April 11, 2011
- Will New Anti-AD Drugs Be Able to Take Significant Share from Aricept?
April 11, 2011
- Nipro to Create Medical Device Joint Venture in Bangladesh
April 11, 2011
- Toyama Chemical Applies for Anti-flu Drug T-750
April 11, 2011
- Full Operations Still on Hold at Utsunomiya Plant: Chugai
April 11, 2011
- Simultaneous Vaccination with 2 Vaccines Resumed from April 1
April 11, 2011
- FDA Approves Long-acting Treatment for OA Knee Pain: Seikagaku
April 11, 2011
- Korosho Asks METI to Exclude Drug Production Facilities from Planned Electricity Outages
April 11, 2011
- NICE Recommends Aricept for Mild AD
April 11, 2011
- Seikagaku Withdraws PMA for Additional Indication of Supartz in the US
April 11, 2011
- Earthquake Disrupts Production of Some Raw Materials
April 11, 2011
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…